Single-dose aprepitant vs ondansetron for the prevention of postoperative nausea and vomiting: A randomized, double-blind Phase III trial in patients undergoing open abdominal surgery

British Journal of Anaesthesia

Volumn 99, Issue 2, 2007, Pages 202-211

  Diemunsch, Pierre ^a   Gan, T J ^b   Philip, B K ^c   Girao, M J ^d   Eberhart, L ^e   Irwin, M G ^f   Pueyo, J ^g   Chelly, J E ^h   Carides, A D ⁱ   Reiss, T ⁱ   Evans, J K ⁱ   Lawson, F C ⁱ  

^a HÔPITAL DE HAUTEPIERRE   (France)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^e PHILIPPS UNIVERSITY MARBURG   (Germany)

^f UNIVERSITY OF HONG KONG   (Hong Kong)

^g UNIVERSITY CLINIC OF NAVARRA   (Spain)

^h UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

ⁱ MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Antagonism; Aprepitant; Clinical trials; Ondansetron; PONV; Serotonin (5 hydroxy tryptamine)

Indexed keywords

APREPITANT; BENZODIAZEPINE; BETAMETHASONE; CYCLIZINE; DEXAMETHASONE; DIMENHYDRINATE; DOLASETRON MESILATE; DROPERIDOL; GRANISETRON; HALOPERIDOL; INHALATION ANESTHETIC AGENT; LORAZEPAM; METOCLOPRAMIDE; MIDAZOLAM; NEOSTIGMINE; NEUROMUSCULAR BLOCKING AGENT; NITROUS OXIDE; ONDANSETRON; OPIATE; PLACEBO; PROCHLORPERAZINE; PROMETHAZINE; SCOPOLAMINE;

ABDOMINAL SURGERY; ADULT; AGED; ANESTHESIA INDUCTION; ARTICLE; BRADYCARDIA; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; ERYTHROCYTE; FEMALE; GENERAL ANESTHESIA; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MAJOR SURGERY; MALE; MULTICENTER STUDY; NAUSEA; PHASE 3 CLINICAL TRIAL; POSTOPERATIVE NAUSEA AND VOMITING; POSTOPERATIVE PERIOD; PREOPERATIVE CARE; PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SIDE EFFECT; SINGLE DRUG DOSE;

EID: 34547866543     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/aem133     Document Type: Article

References (37)

1. Watcha MF, White PF. Postoperative nausea and vomiting: Its etiology, treatment, and prevention. Anesthesiology 1992; 77: 162-84
2. Cohen MM, Duncan PG. DeBoer DP, Tweed WA. The postoperative interview. assessing risk factors for nausea and vomiting. Anesth Analg 1994; 78: 7-16
3. Apfel CC, Läärä E, Koivuranta M, Greim C-A. Roewer N. A simplified risk score for predicting postoperative nausea and vomiting. Anesthesiology 1999; 91: 693-700
4. Gan TJ, Ginsberg B, Grant AP, Glass PSA. Double-blind, randomized comparison of ondansetron and intraoperative propofol to prevent postoperative nausea and vomiting. Anesthesiology 1996; 85: 1036-42
5. Koivuranta M, Läärä E, Snare L, Alahuhta S. A survey of post-operative nausea and vomiting. Anaesthesia 1997; 52: 449
6. Rust M, Cohen LA. Single oral dose ondansetron in the prevention of postoperative nausea and emesis. Anaesthesia 1994; 49: 16-23
7. 1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets. Neuropharmacology 1996; 35: 1121-9
8. 1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets. Neuropharmocology 1999; 39: 652-63
9. 1 receptor antagonist CP-99,994. Neuropharmacology 1994; 33: 259-60
10. Leslie RA. Neuroactive substances in the dorsal vagal complex of the medulla oblongata: Nucleus of the tractus solitarius, area postrema, and dorsal motor nucleus of the vagus. Neurochem Int 1985; 7: 191-211
11. Grunberg SM, Hesketh PJ. Control of chemotherapy-induced emesis. N Engl J Med 1993; 329: 1790-6
12. Veyrat-Follet C, Farinotti R, Palmer JL Physiology of chemotherapy-induced emesis and antiemetic therapy. Predictive models for evaluation of new compounds. Drugs 1997; 53: 206-34
13. Amin AH, Crawford TB, Gaddum JH. The distribution of substance P and 5-hydroxy-tryptamine in the central nervous system of the dog. J Physiol 1954, 126: 596-618
14. Diemunsch P, Grelot L. Potential of substance P antagonists as antiemetics. Drugs 2000; 60: 533-46
15. Gesztesi Z, Scuderi PE, White PF et al. Substance P (Neurokinin-1) antagonist prevents postoperative vomiting after abdominal hysterectomy procedures. Anesthesiology 2000; 93: 931-7
16. Diemunsch P, Schoeffler P, Bryssine B, et al. Antiemetic activity of the NKI receptor antagonist GR205171 in the treatment of established postoperative nausea and vomiting after major gynaecological surgery. Br J Anaesth 1999; 82: 274-6
17. Merck & Co., Inc. EMEND® capsules (aprepitant). In: Physicians Desk Reference, 61st Edn. Montvale, NJ: Thomson PDR, 2007; 1963-1969
18. 1 antagonist, aprepitant, versus ondansetron for the prevention of postoperative nausea and vomiting. Anesth Analg 2007; 104: 1082-9
19. GlaxoSmithKline. ZOFRAN® (ondansetron hydrochloride) injection and ZOFRAN® (ondansetron hydrochloride) injection premixed. In: Physicians Desk Reference, 61 st Edn. Montvale, NJ: Thomson PDR. 2007; 1634-1639
20. Aldrete JA, Kroulik D. Anesthesia and analgesia. Curr Res 1970; 49: 924-33
21. FDA USDoHaHS. Changes or modifications during the conduct of a clinical investigation; final guidance for industry and CDRH staff. 2001. Available from http://www.fda.gov/cdrh/ode/guidance/1337.pdf
22. EMEND 40 mg hard capsule. Summary of product chararacteristics.2006 Available from http://www.emea.eu.int/humandocs/PDFs/EPAR/emend/ H-527-PI-en.pdf
23. Apfel CC, Korttila K, Abdalla M, et al. A factorial trial of six interventions for the prevention of postoperative nausea and vomiting. N Engl J Med 2004, 350: 2441-51
24. Boogaerts JG, Vanacker E, Seidel L, Albert A. Bardiau F. Assessment of postoperative nausea using a visual analogue scale. Acta Anaesthesiol Scand 2000; 44: 470-4
25. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med 1985; 4: 213-26
26. Kovac AL, O'Connor TA, Pearman MH, et al. Efficacy of repeat intravenous dosing of ondansetron in controlling post-operative nausea and vomiting: A randomized, double-blind, placebo-controlled multicenter trial. J Clin Anesth 1999; 11: 453-9
27. Tang J, Wang B, White PF, Watcha MF, Qi J, Wender RH. The effect of timing of ondansetron administration on its efficacy, cost-effectiveness, and cost-benefit as a prophylactic antiemetic in the ambulatory setting. Anesth Analg 1998; 86: 274-82
28. Candiotti K, Birnbach D, Lubarsky D, Nhuch F, Kamat A, Koch W. The impact of pharmacogenomics on postoperative nausea and vomiting: Do CYP2D6 allele copy number and polymorphisms affect the success or failure of ondansetron prophylaxis? Anesthesiology 2005; 102 543-9
29. Sanchez LA, Hirsch JD. Identification of cost consequences as the critical step in a cost-of-illness study: Postoperative nausea and vomiting in an ambulatory surgery center example. J Res Pharm Econ 1992; 4: 41-53
30. Carroll NV, Miederhoff P, Cox FM, Hirsch JD. Postoperative nausea and vomiting after discharge from outpatient surgery centers. Anesth Analg 1995; 80: 903-9
31. Hirsch J. Impact of postoperative nausea and vomiting in the surgical setting. Anaesthesia 1994; 49: 30-3
32. Kovac AL. Prevention and treatment of postoperative nausea and vomiting. Drugs 2000, 59: 213-43
33. Nelson TP. Postoperative nausea and vomiting: Understanding the enigma. J Perianesth Nurs 2002; 17: 178-89
34. Atallah FN, Riva A, Nguyen LB. Boerhaave's syndrome after post-operative vomiting. Anesth Analg 2004; 98: 1164-6
35. Eberhart LHJ, Morin AM, Hoerle S, Wulf H, Geldner G. Droperidol and dolasetron alone or in combination for prevention of postoperative nausea and vomiting after vitrectomy. Ophthalmology 2004, 111 1569-75
36. Bremner G, Kumar C. Delayed surgical emphysema, pneumome-diastinum and bilateral pneumothoraces. Br J Anaesth 1993; 71: 296-7
37. Schumann P, Polaner D. Massive subcutaneous emphysema and sudden airway compromise. Anesth Analg 1999; 89: 796-7